XML 51 R40.htm IDEA: XBRL DOCUMENT
v3.21.1

Note 4 - Acquisitions (Details Textual) - Changzhou Eminence Biotechnology [Member] - USD ($) $ in Thousands |  | 5 Months Ended
--- | --- | ---
Oct. 20, 2020 | Mar. 31, 2021 | Mar. 31, 2021
Business Acquisition, Percentage of Voting Interests Acquired | 47.60% |  |
Business Combination, Consideration Transferred, Total | $ 9,800 |  |
Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value | $ 8,985 | $ 8,985 | $ 8,985
Variable Interest Entity, Primary Beneficiary, Maximum Loss Exposure, Portion Stemming from Initial Investment |  | 9,800 | 9,800
Variable Interest Entity, Primary Beneficiary, Maximum Loss Exposure, Portion Stemming from Loans Made |  | 800 | 800
Goodwill, Purchase Accounting Adjustments |  | $ (963) |
Developed Technology Rights [Member] |  |  |
Finite-Lived Intangible Asset, Useful Life (Year) | 13 years |  |
Customer Relationships [Member] |  |  |
Finite-Lived Intangible Asset, Useful Life (Year) | 10 years |  |
Minimum [Member] |  |  |
Variable Interest Entity, Financial or Other Support Expected Amount |  |  | 6,000
Maximum [Member] |  |  |
Variable Interest Entity, Financial or Other Support Expected Amount |  |  | $ 12,000

X
- Definition Represents financial or other support expected amount for variable interest entity. + References No definition available. + Details
Name: | tech_VariableInterestEntityFinancialOrOtherSupportExpectedAmount
Namespace Prefix: | tech_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Portion of the amount of maximum exposure to loss from involvement with consolidated variable interest entity (VIE) stemming from the reporting entity's initial investment in the VIE. + References No definition available. + Details
Name: | tech_VariableInterestEntityPrimaryBeneficiaryMaximumLossExposurePortionStemmingFromInitialInvestment
Namespace Prefix: | tech_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Portion of the amount of maximum exposure to loss from involvement with consolidated variable interest entity (VIE) stemming from the one or more loans made by the reporting entity to the VIE. + References No definition available. + Details
Name: | tech_VariableInterestEntityPrimaryBeneficiaryMaximumLossExposurePortionStemmingFromLoansMade
Namespace Prefix: | tech_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Percentage of voting equity interests acquired at the acquisition date in the business combination. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463 + Details
Name: | us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition This element represents the fair value of the noncontrolling interest in the acquiree at the acquisition date. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (e)(1) -URI http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472 + Details
Name: | us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 30 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 30 -Paragraph 7 -URI http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477 + Details
Name: | us-gaap_BusinessCombinationConsiderationTransferred1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References No definition available. + Details
Name: | us-gaap_FiniteLivedIntangibleAssetUsefulLife
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 25 -Paragraph 16 -URI http://asc.fasb.org/extlink&oid=116868678&loc=d3e961-128460 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (g) -URI http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267 + Details
Name: | us-gaap_GoodwillPurchaseAccountingAdjustments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=tech_ChangzhouEminenceBiotechnologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |